Litcius/Paper detail

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

Biswajit Chowdhury, Albert Z. Luu, Vincent Z. Luu, M. Golam Kabir, Yi Pan, Hwee Teoh, Adrian Quan, Sandra Sabongui, Mohammed Al‐Omran, Deepak L. Bhatt, C. David Mazer, Kim A. Connelly, Subodh Verma, David A. Hess

2020Biochemical and Biophysical Research Communications140 citationsDOI

Topics & Concepts

EmpagliflozinMedicineCanagliflozinCardiologyInternal medicinePulmonary hypertensionBlood pressureHeart failureDiabetes mellitusType 2 diabetesEndocrinologyPulmonary Hypertension Research and TreatmentsHeart Failure Treatment and ManagementPeptidase Inhibition and Analysis
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension | Litcius